Format

Send to

Choose Destination
Clin Perinatol. 2013 Sep;40(3):509-24. doi: 10.1016/j.clp.2013.05.004. Epub 2013 Jul 17.

Management of neonatal abstinence syndrome from opioids.

Author information

1
Department of Anesthesiology, College of Medicine, Mayo Clinic, 200 First Street, Southwest, Rochester, MN 55902, USA.

Abstract

Most infants at risk for neonatal abstinence syndrome have opioid plus another drug exposure; polypharmacy is the rule rather than the exception. Scales for evaluation of neonatal abstinence syndrome are primarily based for opioid withdrawal. A standard protocol to treat neonatal abstinence syndrome has not been developed. Institute nonpharmacologic strategies for all neonates at risk. The American Academy of Pediatrics recommends mechanism-directed therapy (treat opioid withdrawal with an opioid) as the first-line therapy. Second-line medications are currently under evaluation.

KEYWORDS:

Abstinence; Buprenorphine; Methadone; Neonatal; Opioids; Withdrawal

PMID:
23972754
DOI:
10.1016/j.clp.2013.05.004
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center